Seattle Genetics Stock News

Try your hand at morphing science and business for a great investment opportunity in biotech.

The big drugmaker is gaining access to Century Therapeutics' off-the-shelf CAR-T programs.

Seagen Inc (NASDAQ: SGEN) announced data from a Phase 1 trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The data wer

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close o

These two biotech stocks are set to report key clinical data later this year.

Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships

These potential corporate combinations would make a lot of sense.

These potential corporate combinations would make a lot of sense.

We report the most recent holdings and the trading signals for 12/27/2021. Click here to read this week's trading update of Outperforming The S&P 500.

B. Metzler seel. Sohn & Co. Holding AG lessened its position in Seagen Inc. (NASDAQ:SGEN) by 2.0% in the third quarter, HoldingsChannel reports. The firm owned 8,094 shares of the biotechnology company’s stock after selling 166 shares during the quarter. B. Metzler seel. Sohn & Co. Holding AG’s holdings in Seagen were worth $1,374,000 as […]

Janney Montgomery Scott LLC lifted its position in Seagen Inc. (NASDAQ:SGEN) by 15.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,657 shares of the biotechnology companys stock after purchasing an additional 1,704 shares during the quarter. Janney Montgomery Scott [] The post Seagen Inc. (NASDAQ:SGEN) Shares Purchased by Janney Montgomery Scott LLC appeared first on ETF Daily News .

Seagen Inc. (NASDAQ:SGEN) EVP Charles R. Romp sold 1,323 shares of Seagen stock in a transaction that occurred on Monday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $198,251.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available [] The post Charles R. Romp Sells 1,323 Shares of Seagen Inc. (NASDAQ:SGEN) Stock appeared first on ETF Daily News .

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

LV and SEA-CD40 represent the nearest growth drivers. A short-term positive could be a win in a patent dispute with Daiichi. According to my valuation, Seagen's target price is $193.